标题
Role of erbB3 receptors in cancer therapeutic resistance
作者
关键词
-
出版物
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
Volume 46, Issue 3, Pages 190-198
出版商
Oxford University Press (OUP)
发表日期
2014-01-22
DOI
10.1093/abbs/gmt150
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Oncogenic ERBB3 Mutations in Human Cancers
- (2013) Bijay S. Jaiswal et al. CANCER CELL
- Src Family Kinases as Novel Therapeutic Targets to Treat Breast Cancer Brain Metastases
- (2013) S. Zhang et al. CANCER RESEARCH
- Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
- (2013) Ethan V. Abel et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeted therapy for HER2 positive breast cancer
- (2013) Jason A Incorvati et al. Journal of Hematology & Oncology
- Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors
- (2013) D. C. Kirouac et al. Science Signaling
- Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF -Mutant Thyroid Carcinomas
- (2013) Cristina Montero-Conde et al. Cancer Discovery
- Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
- (2012) Dorte L. Nielsen et al. BREAST
- Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation
- (2012) S. Huang et al. CANCER RESEARCH
- Current approaches and future directions in the treatment of HER2-positive breast cancer
- (2012) Sara A. Hurvitz et al. CANCER TREATMENT REVIEWS
- Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK-Positive Non-Small Cell Lung Cancer
- (2012) J. Tanizaki et al. CLINICAL CANCER RESEARCH
- HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis
- (2012) Alberto Ocana et al. JNCI-Journal of the National Cancer Institute
- Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells
- (2012) Martin Bezler et al. Molecular Oncology
- Survivin in Solid Tumors: Rationale for Development of Inhibitors
- (2012) David N. Church et al. Current Oncology Reports
- Resistance to EGFR-Targeted Therapy: A Family Affair
- (2011) Gregory Vlacich et al. CANCER CELL
- Toward the Prognostic Significance and Therapeutic Potential of HER3 Receptor Tyrosine Kinase in Human Colon Cancer
- (2011) A. Beji et al. CLINICAL CANCER RESEARCH
- Targeting survivin in cancer: the cell-signalling perspective
- (2011) Jagat R. Kanwar et al. DRUG DISCOVERY TODAY
- Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors
- (2011) Luigi Aurisicchio et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer
- (2011) Bostjan Seruga et al. JOURNAL OF CLINICAL ONCOLOGY
- Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
- (2011) A Oliver Sartor Journal of Hematology & Oncology
- Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin
- (2011) Ronan J Kelly et al. Molecular Cancer
- Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
- (2011) Siyuan Zhang et al. NATURE MEDICINE
- Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition
- (2011) B N Rexer et al. ONCOGENE
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival
- (2010) Connie G. Chiu et al. ANNALS OF SURGERY
- ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma
- (2010) J. Spencer Liles et al. CANCER BIOLOGY & THERAPY
- An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells
- (2010) Qing Sheng et al. CANCER CELL
- The Rebirth of a Phoenix: Ovarian Cancers Are Addicted to ErbB-3
- (2010) Gordon B. Mills et al. CANCER CELL
- Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin
- (2010) X. Huang et al. CANCER RESEARCH
- HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy
- (2010) M. R. Campbell et al. CLINICAL CANCER RESEARCH
- Mechanisms of resistance to HER family targeting antibodies
- (2010) Tim J. Kruser et al. EXPERIMENTAL CELL RESEARCH
- Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin
- (2010) S Wang et al. ONCOGENE
- H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3
- (2010) A Chakrabarty et al. ONCOGENE
- ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
- (2010) Fumin Shi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics
- (2010) Dhara N. Amin et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- An overview of HER-targeted therapy with lapatinib in breast cancer
- (2009) Heather McArthur ADVANCES IN THERAPY
- ErbB receptors and signaling pathways in cancer
- (2009) Nancy E Hynes et al. CURRENT OPINION IN CELL BIOLOGY
- Estrogenic Promotion of ErbB2 Tyrosine Kinase Activity in Mammary Tumor Cells Requires Activation of ErbB3 Signaling
- (2009) B. Liu et al. MOLECULAR CANCER RESEARCH
- Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study
- (2008) A K Koutras et al. BRITISH JOURNAL OF CANCER
- A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy
- (2008) S. T. Lee-Hoeflich et al. CANCER RESEARCH
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
- HER3 Is a Determinant for Poor Prognosis in Melanoma
- (2008) M. Reschke et al. CLINICAL CANCER RESEARCH
- Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors
- (2008) F. L. Chen et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More